These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30770221)

  • 1. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
    Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL
    Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
    Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
    N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
    Nolan T; Santolaya ME; de Looze F; Marshall H; Richmond P; Henein S; Rheault P; Heaton K; Perrett KP; Garfield H; Gupta A; Ferguson M; D'Agostino D; Toneatto D; O'Ryan M
    Vaccine; 2019 Feb; 37(9):1209-1218. PubMed ID: 30691980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
    Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
    Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
    Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
    Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.